RxDoctor Payments Data

Elizabeth Morrison-Banks, MD

Neurology · Riverside, CANPI 1639259898

Payments from drug & device makers

$57,010in general payments, 2019–2025

Across 65 payments — averaging $877.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$42K
  • EMD Serono, Inc.$8K
  • Genentech USA, Inc.$7K
  • AstraZeneca$146
  • Novartis$141
  • Sanofi-aventis U.S. LLC$59
  • plus $99 from 4 others

What the payments were for

  • Consulting fees$16,54729%
  • Speaking & faculty fees$35,96563%
  • Travel & lodging$3,1686%
  • Food & beverage$1,3272%
  • Education$30%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,010 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$13,795
Medicare patients
59
Services billed
498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcrevusOcrelizumab20$758,148
TysabriNatalizumab58$464,862
CopaxoneGlatiramer Acetate48$292,218
HizentraImmun Glob G(Igg)/Pro/Iga 0-5012$280,520
Kesimpta PenOfatumumab21$171,588
AubagioTeriflunomide12$112,149
TecfideraDimethyl Fumarate12$102,010
AmpyraDalfampridine13$82,341
Dalfampridine ErDalfampridine100$50,898
Teriflunomide13$5,724
Dimethyl Fumarate11$1,755
Gabapentin20$816
Baclofen30$549
Bupropion XlBupropion Hcl14$198
Hydroxyzine Pamoate11$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTysabri, Tecfidera$41,715$566,87270 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.

Other neurology in Riverside

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →